Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2009 1
2010 2
2015 1
2016 1
2017 1
2019 2
2020 1
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Palma DA, et al. J Clin Oncol. 2020 Sep 1;38(25):2830-2838. doi: 10.1200/JCO.20.00818. Epub 2020 Jun 2. J Clin Oncol. 2020. PMID: 32484754 Free PMC article. Clinical Trial.
RESULTS: Between 2012 and 2016, 99 patients were randomly assigned at 10 centers internationally. The most common primary tumor types were breast (n = 18), lung (n = 18), colorectal (n = 18), and prostate (n = 16). ...
RESULTS: Between 2012 and 2016, 99 patients were randomly assigned at 10 centers internationally. The most common primary tumor types were b …
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes.
Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Harrow S, et al. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):611-616. doi: 10.1016/j.ijrobp.2022.05.004. Epub 2022 May 26. Int J Radiat Oncol Biol Phys. 2022. PMID: 35643253 Clinical Trial.
RESULTS: Ninety-nine patients were randomized between 2012 and 2016 (n = 33 in arm 1 vs n = 66 in arm 2). Primary tumor sites included lung (n = 18), breast (n = 18), colon (n = 18), prostate (n = 16), and other (n = 29). ...
RESULTS: Ninety-nine patients were randomized between 2012 and 2016 (n = 33 in arm 1 vs n = 66 in arm 2). Primary tumor sites …
Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
Kopek N, Holt MI, Hansen AT, Høyer M. Kopek N, et al. Radiother Oncol. 2010 Jan;94(1):47-52. doi: 10.1016/j.radonc.2009.11.004. Epub 2009 Dec 4. Radiother Oncol. 2010. PMID: 19963295
METHODS AND MATERIALS: Twenty-seven patients with unresectable cholangiocarcinoma (n=26 Klatskin tumours and one intrahepatic cholangiocarcinoma (IHCC)) were treated by linac-based SBRT. ...
METHODS AND MATERIALS: Twenty-seven patients with unresectable cholangiocarcinoma (n=26 Klatskin tumours and one intrahepatic cholang …
Synthesis of a Far-Red Photoactivatable Silicon-Containing Rhodamine for Super-Resolution Microscopy.
Grimm JB, Klein T, Kopek BG, Shtengel G, Hess HF, Sauer M, Lavis LD. Grimm JB, et al. Angew Chem Int Ed Engl. 2016 Jan 26;55(5):1723-7. doi: 10.1002/anie.201509649. Epub 2015 Dec 11. Angew Chem Int Ed Engl. 2016. PMID: 26661345 Free PMC article.
The rhodamine system is a flexible framework for building small-molecule fluorescent probes. Changing N-substitution patterns and replacing the xanthene oxygen with a dimethylsilicon moiety can shift the absorption and fluorescence emission maxima of rhodamine dyes to long …
The rhodamine system is a flexible framework for building small-molecule fluorescent probes. Changing N-substitution patterns and rep …
Medical and legal evaluation of injuries due to dog bites: a Türkiye study.
Vural T, Erbaş M, Karaca Baysal I. Vural T, et al. Ulus Travma Acil Cerrahi Derg. 2024 Jan;30(1):43-49. doi: 10.14744/tjtes.2024.77550. Ulus Travma Acil Cerrahi Derg. 2024. PMID: 38226579 Free PMC article.
RESULTS: The mean age of the cases was 33.7 years, with 57% being male. 56.4% of the incidents occurred in the city center, and 30.9% took place during the summer months. 65.8% (n=98) of the cases were attributed to stray dogs. Superficial injuries without muscle tissue in …
RESULTS: The mean age of the cases was 33.7 years, with 57% being male. 56.4% of the incidents occurred in the city center, and 30.9% took p …
Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol.
Kidane B, Gerard IJ, Spicer J, Kim JO, Fiset PO, Wawryko P, Cecchini MJ, Inculet R, Abdulkarim B, Fortin D, Qiabi M, Qing G, Enns S, Bashir B, Tankel J, Wakeam E, Warner A, Kopek N, Yaremko BP, Rodrigues GB, Laba JM, Qu M, Malthaner RA, Palma DA. Kidane B, et al. Cancer. 2023 Sep 15;129(18):2798-2807. doi: 10.1002/cncr.34880. Epub 2023 May 23. Cancer. 2023. PMID: 37221679
RESULTS: Seventy-two patients underwent SABR. Most common SABR regimens were 34 Gy/1 (29%, n = 21), 48 Gy/3-4 (26%, n = 19), and 50/55 Gy/5 (22%, n = 16). ...Surgery was reported as being more difficult because of SABR in 38% (n = 10) of cases. Thirtee …
RESULTS: Seventy-two patients underwent SABR. Most common SABR regimens were 34 Gy/1 (29%, n = 21), 48 Gy/3-4 (26%, n = 19), a …
Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.
Olson R, Senan S, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman G, Warner A, Palma D. Olson R, et al. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):943-947. doi: 10.1016/j.ijrobp.2019.08.041. Epub 2019 Aug 27. Int J Radiat Oncol Biol Phys. 2019. PMID: 31470091 Clinical Trial.
Median age was 68 years (range, 43-89), and 60% were male. The most common primary tumor types were breast (n = 18), lung (n = 18), colorectal (n = 18), and prostate (n = 16). Most patients (n = 92) had 1 to 3 metastases. Median follow-up was 26 …
Median age was 68 years (range, 43-89), and 60% were male. The most common primary tumor types were breast (n = 18), lung (n = …
Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With "Good Prognosis" Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial.
Kennedy ED, Simunovic M, Jhaveri K, Kirsch R, Brierley J, Drolet S, Brown C, Vos PM, Xiong W, MacLean T, Kanthan S, Stotland P, Raphael S, Chow G, O'Brien CA, Cho C, Streutker C, Wong R, Schmocker S, Liberman S, Reinhold C, Kopek N, Marcus V, Bouchard A, Lavoie C, Morin S, Périgny M, Wright A, Neumann K, Clarke S, Patil NG, Arnason T, Williams L, McLeod R, Brown G, Mathieson A, Pooni A, Baxter NN. Kennedy ED, et al. JAMA Oncol. 2019 Jul 1;5(7):961-966. doi: 10.1001/jamaoncol.2019.0186. JAMA Oncol. 2019. PMID: 30973610 Free PMC article. Clinical Trial.
The median age at the time of surgery was 66 years (range, 37-89 years). Based on MRI, most tumors were midrectal (65% [n = 53]), T2/early T3 (60% [n = 49]), with no suspicious lymph nodes (63% [n = 52]). On final pathology, 91% (n = 75) of tumors were …
The median age at the time of surgery was 66 years (range, 37-89 years). Based on MRI, most tumors were midrectal (65% [n = 53]), T2/ …
14 results